**Table 2:** Current trials on HCQ for COVID-19 treatment

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **SN** | **Trial ID** | **Title** | **Enrolled/expected cases** | **Study type** | **Start date** | **Location**  | **Primary outcome** |
| **Recruiting Trials** |
| 1 | NCT04359537 | Efficacy of Various Doses of HCQ in Pre-Exposure Prophylaxis for COVID-19 (CHEER) | 200 | CT | 01 May 2020 | Pakistan | COVID-19-free survival in experimental arms compared to placebo (TF: 12 wk) |
| 2 | NCT04343092 | Ivermectin Adjuvant to HCQ and Azithromycine in COVID-19 Patients | 50 | CT | 18 Apr 2020 | Iraq | Number of cured patients (TF: 2 wk) |
| 3 | NCT04350281 | Double Therapy With IFN-beta 1b and HCQ | 80 | CT  | 09 Apr 2020 | Hong Kong | Time to negative NPS viral load (TF: 4 wk)  |
| 4 | NCT04355052 | Open Label Study to Compare Efficacy, Safety and Tolerability of HCQ Combined With Azithromycin Compared to HCQ Combined With Camostat Mesylate and to "no Treatment" in SARS CoV-2 Virus (COSTA) | 250 | CT | 11 Apr 2020 | Israel | Clinical status (TF: 7 d)Positive PCR (TF: 7 d) |
| 5 | NCT04329611 | ALBERTA HOPE COVID-19 for the Prevention of Severe COVID-19 Disease | 1660 | CT | 13 Apr 2020 | Canada  | Composite of hospitalization, invasive mechanical ventilation or death within 30 d (TF: within 30d of randomization) |
| 6 | NCT04355026 | Use of Bromhexine and HCQ for Treatment of COVID-19 Pneumonia | 90 | CT | 10 Apr 2020 | Slovenia | Duration of hospitalization (TF: through study completion, an average of 6 months) Duration of disease (TF: through study completion, an average of 6 months) |
| 7 | NCT04340544 | HCQ for the Treatment of Mild COVID-19 Disease (COMIHY) | 2700 | CT | 22 Apr 2020 | Germany | Difference in time to resolution of clinical signs and symptoms of mild COVID-19 treated with HCQ or placebo as assessed by daily self-assessment (TF: 28±2 d) |
| 8 | NCT04329832 | HCQ vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 (HAHPS) | 300 | CT | 30 Mar 2020 | US | COVID ordinal outcomes scale at 14 d (TF: assessed once on d 14 after enrollment) |
| 9 | NCT04351620 | High-dose HCQ for the Treatment of Ambulatory Patients With Mild COVID-19  | 20 | CT | Apr 2020 | US | Tolerability of high dose HCQ as measured by HCQ dose modification (TF: 14 d), discontinuation of HCQ (TF: 14 d), and A/Es (TF: 14 d) |
| 10 | NCT04345692 | A Randomized Controlled Clinical Trial: HCQ for the Treatment of  COVID-19 in Hospitalized Patients (OAHU-COVID19) | 350 | CT | 26 Mar 2020 | US |  Clinical status (TF: clinical Status at d-15) |
| 11 | NCT04334382 | HCQ vs. Azithromycin for Outpatients in Utah With COVID-19 (HyAzOUT) | 1550 | CT | 02 Apr 2020 | US | Hospitalization within 14 d of enrollment (TF: from enrollment to 14 d after enrollment) |
| 12 | NCT04341207 | Epidemiology of  SARS-CoV-2 and Mortality to COVID-19 Disease in French Cancer Patients (ONCOVID) | 1000 | CT | 03 Apr 2020 | France | Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients (TF: up to 3 months)Covid-19 disease-specific mortality rate in cancer patients treated by HCQ and azithromycin (TF: up to 12 months) |
| 13 | NCT04342221 | HCQ for COVID-19 (COV-HCQ) | 220 | CT | 29 Mar 2020 | Germany | Effect of HCQ on in vivo viral clearance (TF: 6 months) |
| 14 | NCT04336332 | Randomized Comparison of Combination Azithromycin and HCQ vs. HCQ Alone for the Treatment of Confirmed COVID-19  | 160 | CT | 01 Apr 2020 | US | Changes in patients viral load (TF: baseline, d 3 and d 6)Second evaluation of changes in patients viral load (TF: d-6) |
| 15 | NCT04372017 | HCQ as Post-Exposure Prophylaxis Against COVID-19 Infection | 1739 | CT | 14 May 2020 | US | Cohort A: Percentage of COVID-19 exposed healthcare workers treated with HCQ with a positive COVID-19 test. (TF: at enrollment completion outcome 1 will be analyzed.)Cohort B: Percentage of COVID-19 exposed high-risk individuals treated with HCQ with a positive COVID-19 test. (TF: at enrollment completion outcome 2 will be analyzed) |
| 16 | NCT04331834 | Pre-Exposure Prophylaxis With HCQ for High-Risk Healthcare Workers During the COVID-19 Pandemic (PrEP\_COVID) | 440 | CT | 03 Apr 2020 | Spain | Confirmed cases of COVID-19 (TF: up to 6 months) |
| 17 | NCT04394442 | HCQ in COVID-19 Patients | 200 | CT | 21 Mar 2020 | Saudi Arabia | Time to viral clearance (TF: 21 d)% of mortality (TF: 60 d) |
| 18 | NCT04362332 | Chloroquine, HCQ or Only Supportive Care in Patients Admitted With Moderate to Severe COVID-19 (ARCHAIC) | 950 | CT | 14 Apr 2020 | Netherlands | Composite endpoint with disease progression (TF: 14 d) |
| 19 | NCT04315896 | HCQTreatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA) | 500 | CT | 14 Apr 2020 | Mexico | All-cause hospital mortality (TF: from date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 d) |
| 20 | NCT04369742 | Treating COVID-19 With HCQ (TEACH) | 626 | CT | 15 Apr 2020 | US | Cumulative incidence of significant A/Es through d 30 (TF: 30 d)Cumulative incidence of grade 3 or 4 A/Es through d 30 (TF: 30 d)Incidence of discontinuation of therapy (TF: 30 d)Severe disease progression composite outcome (TF: 14 d) |
| 21 | NCT04391127 | HCQ and Ivermectin for the Treatment of COVID-19 Infection | 200 | CT | 04 May 2020 | Mexico | Mean d of hospital stay (TF: 3 months)Rate of respiratory deterioration, requirement of invasive mechanical ventilation or dead (TF: 3 months)Mean of oxygenation index delta (TF: 3 months) |
| 22 | NCT04370782 | HCQ and Zinc With Either Azithromycin or Doxycycline for Treatment of  COVID-19 in Outpatient Setting | 750 | CT | 28 Apr 2020 | US | Time to Resolution of Symptoms relative to baseline (TF: d-5)Time to Resolution of Symptoms relative to baseline (d 1 of trial) (TF: d-14)Time to Resolution of Symptoms relative to baseline (d 1 of trial) (TF: d-21)Number of participants hospitalized and/or requiring repeat ER visits (TF: 21 d)ICU Length of Stay (TF: until discharged up to 30 d)Ventilator (TF: until extubated up to 30 d)  |
| 23 | NCT04329923 | The PATCH Trial (Prevention And Treatment of COVID-19 With HCQ (PATCH) | 400 | CT | 09 Apr 2020 | US | Median release from quarantine time(TF: 14 d or less)Rate of hospital discharge (TF: 14 d)Rate of infection (TF: 2 months) |
| 24 | NCT04374019 | Novel Agents for Treatment of High-risk COVID-19 Positive Patients | 240 | CT | 01 May 2020 | US | Clinical Deterioration (TF: 14 d) |
| 25 | NCT04381988 | A Study of HCQ vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy | 132 | CT | 07 May 2020 | US | Cumulative incidence of SARS-CoV-2 infection (TF: within 9 wk) |
| 26 | NCT04358068 | Evaluating the Efficacy of HCQ and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 | 2000 | CT | 01 May 2020 | US | Proportion of participants who died from any cause or were hospitalized (TF: 21-d) |
| 27 | NCT04351516 | Test and Treat COVID-19 65plus+ (COVID65plus) | 350 | CT | 21 Apr 2020 | Germany | Rate of hospitalization or death at d-7 after study inclusion (TF: 7d) |
| 28 | NCT04332094 | Clinical Trial of Combined Use of HCQ, Azithromycin, and Tocilizumab for the Treatment of COVID-19 (TOCOVID) | 276 | CT | 02 Apr 2020 | Spain | In-hospital mortality (TF: 2 wk)Need for mechanical ventilation in the ICU (TF:2 wk) |
| 29 | NCT04318444 | HCQ Post Exposure Prophylaxis for Coronavirus Disease COVID-19 | 1600 | CT | 29 Marc 2020 | US | Number of participants with symptomatic, lab-confirmed COVID-19. (TF: Date of enrollment to 14 d post-enrollment date) |
| 30 | NCT04408456 | Efficacy of HCQ as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 (PEP-Q) | 200 | CT | 01 Mar 2020 | India | Incidence confirmed and probable cases of COVID-19 (TF: 2 wk) |
| 31 | NCT04303507 | Chloroquine/HCQ Prevention of Coronavirus Disease COVID-19 in the Healthcare Setting (COPCOV) | 40,000 | CT | 29 Apr 2020 | Thailand | Number of symptomatic COVID-19 infections (TF: 90d) |
| 32 | NCT04318015 | HCQ Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial) (PHYDRA) | 400 | CT | 14 Apr 2020 | Mexico | Symptomatic COVID-19 infection rate (TF: From date of randomization until the appearance of symptoms or study completion 60 d after treatment start) |
| 33 | NCT04347980 | Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19 (DHYSCO) | 122 | CT | Apr 2020 | France | D-28 mortality (TF: 28d) |
| 34 | NCT04349228 | Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID-19 for Health Professionals (COVID\_2Pro) | 530 | CT | 28 Apr 2020 | Tunisia  | Symptomatic COVID(+) infection rate (TF: 60 d) |
| 35 | NCT04335552 | Pragmatic Factorial Trial of HCQ, Azithromycin, or Both for Treatment of Severe  SARS-CoV-2 Infection | 500 | CT | 17 Apr 2020 | US | WHO ordinal scale measured at 14 d after enrollment (TF: d-14) |
| 36 | NCT04347915 | The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19 | 60 | CT | 06 May 2020 | Korea | The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)(TF: within 15d) |
| 37 | NCT04328285 | Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers (COVIDAXIS) | 1200 | CT | 14 Apr 2020 | France | Occurrence of an symptomatic or asymptomatic SARS-CoV-2 infection among HCWs (TF: up to 2.5 months) |
| 38 | NCT04352933 | PROLIFIC Chemoprophylaxis Trial (COVID-19) | 1000 | CT | 11 May 2020 | UK | Time to positive COVID-19 (TF: up to 90 d) |
| 39 | NCT04341441 | Will HCQ Impede or Prevent COVID-19 (WHIP COVID-19) | 3000 | CT | 07 Apr 2020 | US | To determine if the use of HCQ as preventive therapy decreases the rate of acquisition of SARS-CoV 2 infections and clinical COVID-19 disease in study participants for each randomized treatment arm as compared to placebo. (TF: 8 wk) |
| 40 | NCT04344457 | Evaluate the Efficacy and Safety of Oral HCQ, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 (COVID-19) | 80 | CT | 16 Apr 2020 | US | Improvement of clinical status (TF: up to 28d) |
| 41 | NCT04344379 | Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus (PREP-COVID) | 900 | CT | 15 Apr 2020 | France | To assess the impact of HCQ and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 d of treatment.(TF: 3 months) |
| 42 | NCT04330690 | Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial (CATCO) | 440 | CT | 18 March 2020 | Canada | Efficacy of interventions as assessed by all-cause mortality (TF: 29d) |
| 43 | NCT04328012 | COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With SARS-CoV-2 (COVIDMED) | 4000 | CT | 06 Apr 2020 | US | National Institute of Allergy and Infectious Diseases COVID-19 Ordinal Severity Scale (NCOSS) (TF: 60d) |
| 44 | NCT04346147 | Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19 (Covid-19HUF) | 165 | CT | 13 Apr 2020 | Spain | Time to clinical improvement (TF: baseline to d 14) |
| 45 | NCT04328961 | HCQ for COVID-19 Post-exposure Prophylaxis (PEP) | 2000 | CT | 31 Mar 2020 | US | PCR confirmed SARS-CoV-2 infection (TF: d-1 through d-14 after enrolment and d-28 after enrolment) |
| 46 | NCT04363450 | HCQ as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP) (HCQPreP) | 1700 | CT | 27 Apr 2020 | US | Incidence of symptomatic COVID-19 infection in healthcare workers (TF: 12 wk) |
| 47 | NCT04355702 | COVID-19 in Lupus Patients | 130 | Observational | 01 Mar 2020 | France | prevalence and severity of Covid-19 infection in patients with SLE (TF: 1 d ) |
| 48 | NCT04351191 | PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds (PRECISE) | 400 | CT | 15 Apr 2020 | Pakistan | RT-PCR result (TF: 6th and 7th d ) |
| 49 | NCT04379492 | A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19 | 120 | CT | 05 May 2020 | US | Clinical improvement on the Ordinal Scale for Clinical Improvement (OSCI) (TF: 14 d ) |
| 50 | NCT04384380 | Efficacy and Tolerability of HCQ in Adult Patients With COVID-19 | 45 | CT | 01 Apr 2020 | Taiwan | Time to negatively RT-PCR (TF: 14 d ) |
| 51 | NCT04370262 | Multi-site Adaptive Trials Using Hydroxycholoroquine for COVID-19 (MATCH) | 1170 | CT | 07 Apr 2020 | US | Mortality (TF: 30 d post hospitalization ) |
| 52 | NCT04332991 | Outcomes Related to COVID-19 Treated With HCQ Among In-patients With Symptomatic Disease (ORCHID) | 510 | CT | 02 Apr 2020 | US | COVID Ordinal Outcomes Scale on d-15 (TF: assessed on study d-15 ) |
| 53 | NCT04334148 | Healthcare Worker Exposure Response and Outcomes of HCQ (HERO-HCQ) | 15000 | CT | 22 Apr 2020 | US | Number of participants with clinical infection with COVID-19 infection (TF: 30 d ) |
| 54 | NCT04344444 | Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease (RCT) | 600 | CT | 10 Apr 2020 | US | Most severe outcome (TF: 5 d ) |
| 55 | NCT04321616 | The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients | 700 | CT | 28 March 2020 | Norway | In-hospital mortality (TF: 3 wk ) |
| 56 | NCT04358081 | HCQ Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease | 444 | CT | 01 May 2020 | US | Percentage of participants who achieve clinical response (TF: 15 d ) |
| 57 | NCT04345861 | HCQ Plus Azithromycin Versus HCQ for COVID-19 Pneumonia (COVIDOC Trial) (COVIDOC) | 150 | CT | 11 Apr 2020 | France | Time to clinical improvement of at least 1 level on the ordinal scale between d-1 (d of the first administration of study drug) to d-11. (TF: up to d-11 ) |
| 58 | NCT04321278 | Safety and Efficacy of HCQ Associated With Azithromycin in SARS-CoV-2 Virus (Coalition COVID-19 Brasil II) | 440 | CT | 28 Mar 2020 | Brazil | Evaluation of the clinical status (TF: 15 d after randomization ) |
| 59 | NCT04373044 | Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19 | 144 | CT | 24 Apr 2020 | US | Proportion of patients requiring invasive mechanical ventilation or dying (TF: up to 14 d ) |
| 60 | NCT04334928 | Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel (EPICOS) | 4000 | CT | 15 Apr 2020 | Spain | Number of confirmed symptomatic infections of SARS-CoV-2 (COVID-19) (TF: 12 wk ) |
| 61 | NCT04354870 | COVID-19 PrEP HCW HCQ Study | 350 | CT | 03 Apr 2020 | US | Frequency of seroconversion to SARS-CoV-2 (TF: baseline, 30d, 60d, 90 d ) |
| 62 | NCT04341493 | HCQ vs Nitazoxanide in Patients With COVID-19 | 86 | CT | 06 Apr 2020 | Mexico | Mechanical ventilation requirement (TF: Since the diagnosis until two wk after ) |
| 63 | NCT04333654 | HCQ in Outpatient Adults With COVID-19 | 210 | CT | 12 Apr 2020 | US | Change from baseline to d-3 in nasopharyngeal SARS-CoV-2 viral load (TF: baseline to d-3 )Number of participants by PCR result status (TF: baseline to d-3  |
| 64 | NCT04346667 | Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds (PEACE) | 400 | CT | 14 Apr 2020 | Pakistan  | RT-PCR negative status (TF: 6-7 d ) |
| 65 | NCT04322396 | Proactive Prophylaxis With Azithromycin and HCQ in Hospitalized Patients With COVID-19 (ProPAC-COVID) | 226 | CT | 06 Apr 2020 | Denmark | Number of d alive and discharged from hospital within 14 d (TF: 14 d ) |
| 66 | NCT04326725 | Proflaxis Using HCQ Plus Vitamins-Zinc During COVID-19 Pandemia | 80 | Observational  | 20 Mar 2020 | Turkey | Protection against COVID-19 (TF: 4 months ) |
| 67 | NCT04325893 | HCQ Versus Placebo in COVID-19 Patients at Risk for Severe Disease (HYCOVID) | 1300 | CT | 01 Apr 2020 | France | Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 d following inclusion and start of treatment. (TF: D 14 ) |
| 68 | NCT04345289 | Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia (CCAP) | 1500 | CT | 01 May 2020 | Denmark | All-cause mortality or need of invasive mechanical ventilation (TF: 28 d ) |
| 69 | NCT04342169 | University of Utah COVID-19 Hydrochloroquine Trial | 400 | CT | 14 Apr 2020 | US | Duration of viral shedding (TF: d-1-14 ) |
| 70 | NCT04321993 | Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients | 1000 | CT | 17 Apr 2020 | Canada | Clinical status of subject at d 15 (on a 7 point ordinal scale). (TF: up to 15 d ) |
| 71 | NCT04364022 | Efficacy of Pragmatic Same-d COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland (COPEP) | 420 | CT | Apr 2020 | Switzerland | 21-d incidence of COVID-19 in individuals exposed to SARS-CoV- 2 who are asymptomatic at baseline. (TF: 21d ) |
| 72 | NCT04353037 | PATCH 2&3:Prevention & Treatment of COVID-19 (SARS-CoV-2) With HCQ | 850 | CT | 07 Apr 2020 | US | Sub Study 1: Patients (TF: 21 d )Sub Study 2: HCWs (TF: 2 months) |
| 73 | NCT04398004 | Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early (ACHIEVE) | 90 | CT | 06 May 2020 | Greece | Clinical outcome negative for two parameters(hospital admission/disease progression) (TF: d-1 to d-8At least 50% change of the score of respiratory symptoms from the baseline (TF: d-1 to d-8 ) |
| 74 | NCT04371744 | QT-Logs : Artificial Intelligence for QT Interval Analysis of ECG From Smartwatches in Patient Receiving Treatment for COVID-19 (QT-Logs) | 100 | Observatonal  | 17 Apr 2020 | France | Corrected QT (QTc) interval measurement (TF: 10 d ) |
| 75 | NCT04341727 | HCQ, HCQ,Azithromycin in the Treatment of SARS-CoV-2 Infection (WU352) | 500 | CT | 04 Apr 2020 | US | Hours to recovery (TF: 42 d ) |
| 76 | NCT04354428 | Treatment for COVID-19 in High-Risk Adult Outpatients | 630 | CT | 16 Apr 2020 | US | LRTI rates (TF: 28 d )Incidence of hospitalization or mortality (TF: d-28)Change in upper respiratory viral shedding (TF: d-1 through d-14) |
| 77 | NCT04366089 | Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora (PROBIOZOVID) | 152 | CT | 26 Mar 2020 | Italy | Delta in the number of patients requiring orotracheal intubation despite treatment (TF: 21 d ) |
| 78 | NCT04315948 | Trial of Treatments for COVID-19 in Hospitalized Adults (Discovery) | 3100 | CT | 22 Mar 2020 | France | Percentage of subjects reporting each severity rating on a 7-point ordinal scale (TF: d-15 ) |
| 79 | NCT04304053 | Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention (HCQ4COV19) | 3040 | CT | 18 Mar 2020 | Spain | Effectiveness of chemoprophylaxis assessed by incidence of secondary COVID-19 cases (TF: up to 14 d after start of treatment ) |
| 80 | NCT04381936 | Randomized Evaluation of COVID-19 Therapy (RECOVERY) | 12000 | CT | 19 Mar 2020 | UK | All-cause mortality (TF: within 28 d) |
| 81 | NCT04366245 | Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection | 72 | CT | 23 Apr 2020 | Spain  | Safety (TF: 30 d )Efficacy: (TF: d+21after randomization ) |
| 82 | NCT04324463 | Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial (ACT COVID19) | 1500 | CT | 21 Apr 2020 | Canada | Outpatients: Hospital Admission or Death (TF: up to 6 wk post randomization )Inpatients: Invasive mechanical ventilation or mortality (TF: up to 6 wk post randomization ) |
| 83 | NCT04373824 | Max Ivermectin- COVID-19 Study Versus Standard of Care Treatment for COVID-19 Cases. A Pilot Study | 50 | CT | 25 Apr 2020 | India | Effect of Ivermectin on eradication of virus. (TF: 3 months ) |
| 84 | NCT04323345 | Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus | 1000 | CT | 15 Apr 2020 | Egypt | Rate of recovery from positive to negative swaps (TF: 14 d )Fever to normal temperature in d (TF: 14 d )Resolution of lung inflammation in CT or X ray (TF: 30 d ) |
| 85 | NCT04331470 | Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19  | 30 | CT | 04 Apr 2020 | Iran | Clear chest CT-scan (TF: between 3-7 d )PCR test (TF: between 3-7 d ) |
| 86 | NCT04366206 | Factors Associated With Clinical Outcomes in Patients Hospitalized for COVID-19 in GHT-93 Est | 143 | Observational | 14 Mar 2020 | France | Composite of death and mechanical ventilation (TF: at 14-d follow-up ) |
| 87 | NCT04333355 | Safety in Convalescent Plasma Transfusion to COVID-19  | 20 | CT | 25 May 2020 | Mexico | Side effects (TF: 14 d ) |
| 88 | NCT04365764 | Effect of Treatments in Patients Hospitalized for Severe COVID-19 Pneumonia: a Multicenter Cohort Study | 400 | Observationa | 14 Mar 2020 | France | Composite of death and mechanical ventilation (TF: 14-d follow-up ) |
| 89 | NCT04380818 | Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 | 106 | CT | 08 May 2020 | Spain | Efficacy of low-dose pulmonary irradiation (TF: d 2 after interventional radiotherapy ) |
| 90 | NCT04359667 | Serum IL-6 and Soluble IL-6 Receptor in Severe COVID-19 Pneumonia Treated With Tocilizumab (UHID-COVID19) | 30 | Observational | 16 Apr 2020 | Croatia | Serum IL-6 and soluble IL-6 receptor as biomarkers of clinical outcomes in patients with severe COVID-19 pneumonia treated with tocilizumab (TF: baseline, 24 hrs post treatment, 48 hrs post treatment, on d-7, and d-28) |
| 91 | NCT04394182 | Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 (ULTRA-COVID) | 15 | CT | 21 Apr 2020 | Spain | Oxygen therapy status at d-2 (TF: at 2 d )Oxygen Saturation at d-2 (TF: at 2 d) |
| 92 | NCT04351724 | Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) (ACOVACT) | 500 | CT | 16 Apr 2020 | Australia | Sustained improvement (>48h) of one point on the WHO Scale (TF: Inclusion to d- 29) |
| 93 | NCT02735707 | Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (REMAP-CAP) | 7100 | CT | 11 Apr 2020 | New Zealand | All-cause mortality (TF: d-90 )Day alive and outside of ICU (TF: d-21) |
| 94 | NCT04316377 | Norwegian Coronavirus Disease 2019 Study (NO COVID-19) | 202 | CT | 25 Mar 2020 | Norway | Rate of decline in SARS-CoV-2 viral load (TF: baseline and at 96 hrs) |
| 95 | NCT04344951 | Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial (HOPE) | 60 | CT | 06 Apr 2020 | Greece | 50% reduction in symptom score for patients with LRTIs (TF: d- 8 visit from study initiation )Lack of progression for patients with URTIs (TF: d-8 visit from study initiation |
| 96 | NCT04335305 | Checkpoint Blockade in COVID-19 Pandemic (COPERNICO) | 24 | CT | 29 May 2020 | Spain | Percentage of patients with normalization of oxygen saturation (TF: through d-14) |
| 97 | NCT04364698 | Observational Cohort of COVID-19 Patients at Raymond-Poincare (COVID-RPC) | 500 | Observational | 07 May 2020 | France | Clinical, biological and radiological characteristics (TF: through study completion, an average of 1 month ) |
| 98 | NCT04405310 | Convalescent Plasma of COVID-19 to Treat SARS-CoV-2 a Randomized Doble Blind 2 Center Trial (CPC-SARS) | 80 | CT | 20 May 2020 | Mexico | Death (TF: 15 d ) |
| 99 | NCT04333589 | Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive | 210 | CT | 01 Apr 2020 | China | Viral nucleic acid test negative conversion rate (TF: 5 months ) |
| 100 | NCT04374539 | Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial (REP-COVID) | 116 | CT | 29 Apr 2020 | Spain | Impact of plasma exchange (TF: 28 d ) |
| 101 | NCT04308668 | Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP) | 3000 | CT | 17 Mar 2020 | US | Incidence of COVID19 and overall change in disease severity over 14d among those who are asymptomatic at baseline (TF: 14 d ) |
| 102 | NCT04335123 | Study of Open Label Losartan in COVID-19  | 50 | CT | 25 Mar 2020 | US | Number of participants with treatment-related adverse events as assessed by protocol definition of AE (TF: 14 d of losartan treatment ) |
| 103 | NCT04278404 | Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02) | 5000 | Observational | 05 Mar 2020 | US | Clearance, Volume of distribution, Elimination rate constant, Half-life, Absorption rate constant, AUC, Maximum concentration, Time to maximum plasma concentration (TF: data will be collected up to 90 d from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210d)  |
| **Not yet recruiting trials** |
| 1 | NCT04338906 | Combination Therapy With Camostat Mesilate + HCQ for COVID-19 (CLOCC) | 334 | CT | 01 June 2020 | NP | Not hospitalized (TF: d-14 from baseline ) |
| 2 | NCT04328272 | Effectiveness of HCQ in COVID-19 Patients (Covid) | 75 | CT | 28 Mar 2020 | Pakistan | National Early Warning Score equal to zero (TF: 3-5 d) |
| 3 | NCT04365231 | HCQ Azithromycin COVID-19 Pregnancy Trial (HASCOPT) | 50 | CT | Apr 2020 | France | Percentage of patients with a negative RT-PCR test result to COVID-19 (TF: 7 d ) |
| 4 | NCT04346329 | Immune Monitoring of Prophylactic Effect of HCQ in Healthcare Providers Highly Exposed to COVID-19 (Chloroquine UN) | 86 | Ct | 20 Apr 2020 | Colombia | Adverse effects (TF: 6 months after administration of HCQ or placebo ) |
| 5 | NCT04387760 | Favipiravir vs HCQ in COVID-19  | 150 | CT | 14 May 2020 | Bahrain | Primary outcome measure will be time to viral clearance (TF: through study completion up to 21 d ) |
| 6 | NCT04382625 | HCQ in SARS-CoV-2 (COVID-19) Pneumonia Trial | 120 | CT | May 2020 | US | Change from baseline oxygenation on d-1 to d-5 (TF: d-1 of treatment to d-5 of treatment ) |
| 7 | NCT04371406 | Efficacy of Azithromycin-associated HCQ Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients (MG-COVID) | 2770 | CT | 02 May 2020 | France | Rate of patients with occurrence of an unfavorable outcome between randomization and d 14 (TF: between randomization and d14 )Primary outcome of ancillary virological study : evolution of viral load between d-0 and d-14 (TF: between d-0 and d-14 ) |
| 8 | NCT04392973 | FAvipiravir and HCQ Combination Therapy (FACCT) | 520 | CT | May 2020 | Saudi Arabia | Clinical Improvement (TF: 28 d ) |
| 9 | NCT04364815 | The University of the Philippines HCQ PEP Against COVID-19 Trial | 960 | CT | May 2020 | Philippines  | Efficacy of HCQ Prophylaxis in Preventing COVID-19 infection (TF: 30 d ) |
| 10 | NCT04363866 | A Pilot Study to Assess HCQ in Patients With SARS-CoV-2 (COVID-19) | 40 | CT | May 2020 | US | Clinical Status at d-5 Assessed by a 6-Point Ordinal Scale (TF: d-5 ) |
| 11 | NCT04361318 | HCQ and Nitazoxanide Combination Therapy for COVID-19  | 100 | CT | May 2020 | Egypt | Number of patients with COVID-19-negative PCR (TF: within 10 d to become PCR negative ) |
| 12 | NCT04392128 | Study Evaluating the Efficacy of HCQ and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) (HYACINTHE) | 114 | CT | 12 May 2020 | France | Evaluation of the efficacy of HCQ and azithromycin on the viral load drop at d 5. (TF: 5 d of treatment ) |
| 13 | NCT04377646 | A Study of HCQ and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers (COVID-Milit) | 660 | CT | 04 May 2020 | Tunisia | SARS CoV2 infection (TF: at 2 months of follow-up ) |
| 14 | NCT04385264 | #StayHome: Early HCQ to Reduce Secondary Hospitalisation and Household Transmission in COVID-19 (#StayHome) | 800 | CT | 12 May 2020 | Switzerland | Proportion of poor outcomes (TF: during the period that the subject is considered as COVID-19-positive: average of 11 d ) |
| 15 | NCT04374903 | HCQ in Combination With Azithromycin or Sirolimus for Treating COVID-19 Patients (COVID19-HOPE) | 58 | CT | 01 May 2020 | Jordan | Time to clinical improvement (TF: 28 d ) |
| 16 | NCT04405921 | HCQ, Azithromycin in the Treatment of COVID-19 (PACTT) | 200 | CT  | May 2020 | Tunisia  | Clinical recovery at d-14, from the start of treatment. (TF: 14 d ) |
| 17 | NCT04359953 | Efficacy of HCQ, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 (COVID-Aging) | 1600 | CT | 24 Apr 2020 | France | Two-week survival rate (TF: d-14 ) |
| 18 | NCT04347889 | Preventing COVID-19 in Healthcare Workers With HCQ: A RCT | 1212 | CT | 20 Apr 2020 | NP | COVID-19 Seroconversion rate (TF: 3 months ) |
| 19 | NCT04323631 | HCQ for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death | 1116 | CT | Mar 2020 | Israel | Number patients developing severe infection or death (TF: within 28 d ) |
| 20 | NCT04397328 | COVID-19 PEP- High-risk Individuals in Long-term and Specialized Care - Canada | 336 | CT | 19 May 2020 | London | Incidence of symptoms with confirmed PCR+ result for SARS-CoV-2. (TF: baseline through d-90 ) |
| 21 | NCT04371926 | Prophylactic Benefit of HCQ in COVID-19 Cases With Mild to Moderate Symptoms and in Healthcare Workers With High Exposure Risk (PREVENT) | 64 | CT | June 2020 | US | Time to reach normal body temperature (TF: 1 month )Development of COVID-19 symptoms during HCQ preventive therapy in staff (TF: 1 month)  |
| 22 | NCT04330586 | A Trial of Ciclesonide in Adults With Mild COVID-19  | 141 | CT | 01 Apr 2020 | Korea | Rate of SARS-CoV-2 eradication at d-14 from study enrollment (TF: hospital d-14 ) |
| 23 | NCT04389359 | PROphylaxis for paTiEnts at Risk of COVID-19 infection (PROTECT) | 1500 | CT | May 2020 | UK | Time to confirmed diagnosis of COVID-19 (TF: to study completion, average 6 months ) |
| 24 | NCT04347512 | Evaluation of the Efficacy of the HCQ-Azithromycin Combination in the Prevention of COVID-19 Related SDRA (TEACHCOVID) | 405 | CT | 01 May 2020 | France | Rate of patients reaching a significant hypoxemia, in each arms. (TF: from d-0 to d-7 ) |
| 25 | NCT04330144 | HCQ as Post Exposure Prophylaxis for SARS-CoV-2(HOPE Trial) | 2486 | CT | 01 Apr 2020 | Korea | The rate of COVID-19 (TF: PCR test of COVID-19 at 14 d after the contact from confirmed case ) |
| 26 | NCT04354597 | HCQ and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID-19 Patients (MOPHYDA) | 200 | CT | 01 May 2020 | Jordan | Effect of HCQ and Azithromycin in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients (TF: 4 months ) |
| 27 | NCT04330495 | Randomized, Controlled, Double-blind Clinical Trial Comparing the Efficacy and Safety of Chemoprophylaxis With HCQ in Patients Under Biological Treatment and / or JAK Inhibitors in the Prevention of SARS-CoV-2 Infection | 800 | CT | 06 Apr 2020 | Spain  | Incidence rate of new COVID-19 cases in both arms (TF: from d-14 after start of treatment up to the end of follow-up: wk-27 )Prevalence, mortality, and ICU of COVID-19 cases in both arms (TF: 27 wk) |
| 28 | NCT04338698 | HCQ, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT (PROTECT) | 500 | CT | 07 Apr 2020 | Pakistan  | Laboratory result (TF: d-07 on follow-up )Clinical outcome (TF: d-07 on follow-up ) |
| 29 | NCT04390594 | Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj) | 258 | CT | 01 Jun 2020 | Senegal | SARS-CoV-2 viral load level (TF: d-7 ) |
| 30 | NCT04360759 | Chloroquine Outpatient Treatment Evaluation for HIV- COVID-19 (CQOTE) | 560 | CT | 01 May 2020 | South Africa | Event-free survival at 28 d post-randomization between experimental group and standard of care group (TF: d-28 ) |
| 31 | NCT04372082 | HCQ or Diltiazem-Niclosamide for the Treatment of COVID-19 (HYdILIC) | 480 | CT | May 2020 | France | Death (TF: at d 14 )Clinical worsening (composite criteria) (TF: at d 14 )Assisted-ventilation and/or hospitalization (composite criteria) (TF: at d 14 ) |
| 32 | NCT04372628 | Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 (TREAT NOW) | 900 | CT | 31 May 2020 | US | Modified COVID ordinal outcomes scale: study d-15 (TF: d-15 ) |
| 33 | NCT04374552 | Asymptomatic COVID-19 Trial (ACT) | 140 | CT | 05 May 2020 | US | The primary outcome is the rate of decline in viral load over the 10 d after randomization (TF: 10 d ) |
| 34 | NCT04359316 | Azithromycin in Hospitalized COVID-19 Patients (AIC) | 40 | CT | 20 Apr 2020 | Iran | Time to clinical improvement (TF: from date of randomization until 14 d later) |
| 35 | NCT04354441 | Effect of HCQ in COVID-19 Positive Pregnant Women (HyPreC) | 600 | CT | May 2020 | Canada | COVID-19-related hospital admissions (TF: hospital admission) |
| 36 | NCT04370015 | HCQ Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers. | 374 | CT | 15 May 2020 | Pakistan | Prevention of SARS-CoV-2 as determined by negative RT-PCR at the end of 12 wk study period Safety as determined by presence or absence of any adverse event related with HCQ treatment (TF: From date of randomization until the appearance of symptoms or study completion 12 wk after treatment initiation ) |
| 37 | NCT04400019 | Prevention of COVID-19 Infection in Nursing Homes by Chemoprophylaxis With HCQ (PREVICHARM) (PREVICHARM) | 1930 | CT | 15 May 2020 | Spain | Number of secondary cases of SARS-CoV-2 infection among residents at 6, 14, and 28 d (TF: Outcome will be evaluated at 6, 14, and 28 d respectively, from the administration of chemoprophylaxis with HCQ )SARS-CoV-2 infection in nursing home staff who provide direct care at 6, 14, and 28d (TF: Outcome will be evaluated at 6,14,and 28 d from the administration of chemoprophylaxis with HCQ ) |
| 38 | NCT04363827 | Protect: Study With HCQ for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19) (PROTECT) | 2300 | CT | 20 May 2020 | Italy  | The proportion of subjects of group 1 who become symptomatic and/or swab positive in each arm within 1 month from randomization. (TF: within 1 month)The proportion of subjects of group 2 who become swab negative in each arm within 14 d from randomization. (TF: within 14 d) |
| 39 | NCT04349592 | Qatar Prospective RCT Of Therapy Eliminating COVID-19 Transmission (Q-PROTECT) | 456 | CT | 14 Apr 2020 | NP | Proportion of virologically cured (no virus detected) cases at d 6 (TF: d-6 ) |
| 40 | NCT04395768 | International ALLIANCE Study of Therapies to Prevent Progression of COVID-19  | 200 | CT | 25 May 2020 | Australia  | Symptoms (TF: once daily for 15 d)LOS (TF: at 15 and 45 d)Invasive mechanical ventilation or mortality (TF: any time within 15 d) |
| 41 | NCT04303299 | Various Combination of Protease Inhibitors, Oseltamivir, Favipiravir, and HCQ for Treatment of COVID-19: A Randomized Control Trial (THDMS-COVID-19) | 320 | CT | 15 Apr 2020 | Thailand | SARS-CoV-2 eradication time (TF: up to 24 wk ) |
| 42 | NCT04351919 | Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID-19(+) (COVID+PA) | 400 | CT | 05 May 2020 | Tunisia | Improvement or healing of clinical signs (TF: at the end of the study treatment - 1 month after inclusion )Evolution of clinical signs (TF: at the end of the study treatment - 1 month after inclusion ) |
| 43 | NCT04359095 | Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia | 1600 | CT | 11 May 2020 | Colombia | Mortality (TF: post-intervention at d 28 )Number of participants with treatment related severe A/Es as assessed by the NCORP Guidance for Collection of A/E related to COVID-19 infection (TF: post-intervention at d 28) |
| 44 | NCT04361461 | Use of HCQ Alone or Associated for Inpatients With SARS-CoV-2 Virus (COVID-19) | 500 | CT | 04 May 2020 | Brazil | Individual response rate (TF: 14d) |
| 45 | NCT04352946 | Health Care Worker Prophylaxis Against COVID-19: The HERO Trial (HERO) | 374 | CT | 14 Apr 2020 | US | Cumulative Incidence of COVID-19 Infection (TF: 90 d ) |
| 46 | NCT04336748 | HCQ for Primary Prophylaxis Against COVID-19 in Health-care Workers | 440 | CT | Apr 2020 | NP | Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR (TF: 4 wk ) |
| 47 | NCT04335084 | A Study of HCQ, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection (HELPCOVID-19) | 600 | CT | May 2020 | US | Prevention of COVID-19 symptoms as recorded in a daily diary (TF: 24 wk )Safety as determined by presence or absence of A/Es and serious A/Es (TF: 24 wk ) |
| 48 | NCT04403100 | HCQ and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1" | 1968 | CT | 28 May 2020 | Brazil | Proportion of participants who were hospitalized for progression of COVID-19 disease (TF: measuring during 28-d)Proportion of participants who died due to COVID-19 progression and/ or complications (TF: measuring during 28-d) |
| 49 | NCT04386070 | Preventing Pulmonary Complications in Surgical Patients at Risk of COVID-19 (PROTECT-Surg) | 6400 | CT | 15 May 2020 | NP | Pneumonia free survival; acute respiratory distress syndrome (ARDS) free survival; or death (TF: from randomisation until discharge from hospital, average less than 30 d ) |
| 50 | NCT04390061 | TOFAcitinib Plus Hydroxycloroquine vs Hydroxycloroquine in Patients With COVID-19 Interstitial Pneumonia (TOFACoV-2) | 116 | CT | Jun 2020 | NP | Prevention of severe respiratory failure requiring mechanical ventilation (TF: 14 d ) |
| 51 | NCT04342156 | Safety And Efficacy Of HCQ For At Risk Population (SHARP) Against COVID-19 (SHARP COVID-19) | 12000 | CT | Apr 2020 | NP | Positive serology or reverse transcriptase (RT-PCR) for COVID-19 up until d 28. (TF: until d 28 ) |
| 52 | NCT04384458 | COVID-19 Prophylaxis With HCQ Associated With Zinc For High-Risk Healthcare Workers | 400 | CT | May 2020 | Brazil | Proportion of participants in whom there was a clinical finding of COVID-19. (TF: d-50Symptomatic COVID-19 infections. (TF: d-50 ) |
| 53 | NCT04371523 | HCQ to Prevent COVID-19 Disease Amongst Healthcare Workers (PROVIDE) | 1100 | CT | 01 May 2020 | Canada | Positive for SARS-CoV-2 (TF: 8 wk ) |
| 54 | NCT04359615 | Favipiravir in Hospitalized COVID-19 Patients (FIC) | 40 | CT | 20 Apr 2020 | Iran | Time to clinical improvement (TF: from date of randomization until 14 d later) |
| 55 | NCT04334512 | A Study of Quintuple Therapy to Treat COVID-19 Infection (HAZDpaC) | 600 | CT | May 2020 | US | The rate of recovery of mild or moderate COVID-19 in patients using quintuple therapy (TF: 12 wk )Reduction or Progression of symptomatic day (TF: 12 wk )Assess the safety of quintuple therapy, via pulse, oxygen saturation, and ECG (TF: 12 wk )Assess tolerability of quintuple therapy (TF: 12 wk ) |
| 56 | NCT04383717 | Levamisole and Isoprinosine in the Treatment of COVID-19: A Proposed Therapeutic Trial | 60 | CT | 05 May 2020 | NP | COVID 19 induced fever in both groups (TF: 4 wk )COVID 19 induced dyspnea in both groups (TF: 4 wk )COVID 19 viral load in both groups (TF: 4 wk ) |
| 57 | NCT04373733 | A Randomised Controlled Trial of Early Intervention in COVID-19: Favipiravir Verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe (PIONEER) | 450 | CT | 01 May 2020 | UK | Time to improvement by two points on a seven-category ordinal scale (TF: Up to 28 d from randomisation ) |
| 58 | NCT04339816 | Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial (AZIQUINE-ICU) | 240 | CT | 20 Apr 2020 | NP | Proportion of alive patients free off mechanical ventilation (TF: 14 d after enrolment ) |
| 59 | NCT04390152 | Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID-19  | 40 | CT | Jun 2020 | Colombia | Intergroup mortality difference with treatment (TF: 28 d) |
| 60 | NCT04332835 | Convalescent Plasma for Patients With COVID-19: A Randomized, Open Label, Parallel, Controlled Clinical Study (CP-COVID-19) | 80 | CT | 01 May 2020 | Colombia | Change in viral load (TF: d-0, 4, 7, 14 and 28 )Change in immunoglobulin M COVID-19 titers (TF: d- 0, 4, 7, 14 and 28 )Change in Immunoglobulin G COVID-19 titers (TF: d- 0, 4, 7, 14 and 28 ) |
| 61 | NCT04365582 | OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome (OUTCOV) | 640 | CT | 28 Apr 2020 | France | Hospital admission (TF: d- 20 ) |
| 62 | NCT04361422 | Isotretinoin in Treatment of COVID-19 (Randomized) | 300 | CT | 21 Apr 2020 | NP | Clinical clearance (TF: 14-30 d ) |
| 63 | NCT04356495 | Treatments to Decrease the Risk of Hospitalization or Death in Elderly Outpatients With Symptomatic SARS-CoV-2 Infection (COVID-19) (COVERAGE) | 1057 | CT | 15 Apr 2020 | France | Proportion of participants with an occurrence of hospitalization (TF: from inclusion (d 0) to d 14 )Death (TF: from inclusion to d-14 ) |
| 64 | NCT04349241 | Efficacy and Safety of Favipiravir in Management of COVID-19 (FAV-001) | 100 | CT | 20 Apr 2020 | Egypt | Viral clearance (TF: 14 d ) |
| 65 | NCT04353245 | Study of Biomarkers in the Long-term Impact of Coronavirus Infection in the Cardiorespiratory System (PostCOVID19) | 130 | Observational | 01 Jun 2020 | Brazil | Fibrosis (TF: 12 months )Ergospirometers (TF: 12 months ) |
| 66 | NCT04386447 | Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19 (OsCOVID19) | 145 | CT | 30 Jun 2020 | France, Italy | Proportion of cases who during 14 exhibit one of the following conditions (TF: 14 d ) |
| 67 | NCT04363060 | Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID-19 Patients With Pneumonia in Non-intensive Unit (AziA) | 104 | CT | 30 Apr 2020 | France  | Rate of positive SARS-CoV-2 RT-PCR (TF: d-6 ) |
| 68 | NCT04386239 | Study on the Use of Sarilumab in Patients With COVID-19 Infection | 40 | CT | May 2020 | NP | Proportion of patients who show an improvement of the respiratory function (TF: 6 wk ) |
| 69 | NCT04401475 | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With Moderate to Severe COVID-19 Pneumonia | 510 | CT | Jul 2020 | NP | An improvement of two points on the seven-point ordinal scale (TF: 28 d ) |
| 70 | NCT04395170 | Convalescent Plasma Compared to Anti- COVID-19 Human Immunoglobulin and Standard Treatment (TE) in Hospitalized Patients | 75 | CT | Jun 2020 | NP | Admission to ICU and/or mechanical ventilation (TF: one year ) |
| 71 | NCT04335201 | Defibrotide in COVID-19 Pneumonia (DEFI-VID19) | 50 | CT | 06 April 2020 | NP | To reduce the progression of acute respiratory failure (TF: 14 d) |
| 72 | NCT04353180 | Assessment the Activity Value of 13- Cis-Retinoic Acid (Isotretinoin) in the Treatment of COVID-19(Randomized) (Isotretinoin) | 360 | CT | May 2020 | Egypt | lung injury score (TF: at 7 and 14 d ) |
| 73 | NCT04403646 | Tannin Specific Natural Extract for COVID-19 Infection (TaCOVID) | 140 | CT | 01 Jun 2020 | NP | Time to hospital discharge (TF: throughout the study) |
| 74 | NCT04320277 | Baricitinib in Symptomatic Patients Infected by COVID-19: an Open-label, Pilot Study. (BARI-COVID) | 200 | CT | 16 May 2020 | Italy | The percentage of patients requiring transfer to ICU as compared with the rate of transfers observed in controls. (TF: 2 wk ) |
| **Active, not recruiting** |
| 1 | NCT04333225 | HCQ in the Prevention of COVID-19 Infection in Healthcare Workers | 228 | CT | 03 Apr 2020  | US | Rate of COVID-19 positive conversion (TF: 7 wk ) |
| 2 | NCT04353271 | Trial of HCQ In COVID-19 Kinetics (THICK) | 58 | CT | 17 Apr 2020 | US | Percentage of virus free subjects (TF: 7d after initiation of trial )Disease severity (TF: 6 d ) |
| 3 | NCT04363203 | VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL) (VA-REACH) | 300 | CT | 30 Apr 2020 | US | D to resolution of cough, fever and shortness of breath (TF: 30-d ) |
| 4 | NCT04345159 | Association Between Long-term HCQ Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease (COVCALL) | 572 | Observational | 15 Apr 2020 | France | Adjusted Odds Ratio (TF: 4 months after inclusion ) |
| 5 | NCT04322123 | Safety and Efficacy of HCQ Associated With Azithromycin in SARS-CoV-2 Virus (COVID-19) (Coalition-I) | 630 | CT | 01 Apr 2020 | Brazil | Evaluation of the clinical status (TF: 15 d after randomization ) |
| 6 | NCT04368351 | Bacteriotherapy in the Treatment of COVID-19 (BACT-ovid) | 70 | Observational | 01 Mar 2020 | Italy | Delta of time of disappearance of acute diarrhea (TF: 21 d ) |
| 7 | NCT04347031 | A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID-19  | 320 | CT | 08 Apr 2020 | Russian Federation | 1st primary endpoint for group 1 (TF: up to 10 d )2nd primary endpoint for group 1 (TF: up to 10 d )1st primary endpoint for group 2 (TF: up to 10 d )2nd primary endpoint for group 2 (TF: through study completion, an average of 3 months ) |
| 8 | NCT04328467 | Pre-exposure Prophylaxis for SARS-Coronavirus-2 | 1500 | CT | 06 Apr 2020 | US | COVID-19-free survival (TF: up to 12 wk ) |
| 9 | NCT04346693 | An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS- COVID-19  | 320 | CT | 08 Apr 2020 | Russian Federation | The change of viral load in patients with SARS-COVID-19. (TF: upon patient inclusion in the study, after 96 hours and on the 10d; )The frequency of development of ADRS (TF: up to 10 d )Duration of hospitalization (TF: up to 10 d )The frequency of early mortality (TF: up to 30 d )The frequency of late mortality (TF: up to 90 d )Clinical status at the time of completion of participation in the study (TF: an average of 10 d ) |
| **Enrolling by invitation** |
| 1 | NCT04345653 | HCQ as Chemoprevention for COVID-19 for High Risk Healthcare Workers | 45 | CT | 14 Apr 2020 | US | Recruitment Feasibility (TF: study period , up to two months from the d the first participant was screened )Recourse utilization (TF: study period , up to two months from the d the first participant was screened )Safety as reflected on the number and severity of adverse events and serious adverse events (TF: 28 d post enrollment )Early feasibility as reflected on the number of participants contracting COVID-19 (10% or less) in comparison to the expected 30% as per CDC. (TF: 28 d post enrollment ) |
| 2 | NCT04334967 | HCQ in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care | 1250 | CT | 30 Mar 2020 | US | Total hospitalization (TF: 14 d )Total mechanical ventilation (TF: 14 d ) |
| 3 | NCT04376814 | Favipiravir Plus HCQ and Lopinavir/Ritonavir Plus HCQ in COVID-19  | 40 | CT | 29 Mar 2020 | Iran | Mortality, long of hospitalization, laboratory treatment response (blood cell count, CRP), dyspnea, oxygen saturation without supplemental oxygen, oxygen therapy (TF: up to 28 d ) |
| 4 | NCT04350684 | Umifenovir in Hospitalized COVID-19 Patients (UAIIC) | 40 | CT | 15 Apr 2020 | Iran | Time to clinical improvement (TF: from date of randomization until 14 d later) |
| 5 | NCT04340349 | Low-dose HCQ and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE) | 140 | CT | 11 May 2020 | Mexico | PCR negative at d-0 plus negative serological panel for COVID-19 antibodies at enrolment. (TF: d-0 )PCR negative at d 30 (TF: d-30 )PCR negative at d 60 (TF: d-60 ) |
| 6 | NCT04347798 | IMPACT: IMPact of Antimalarials on COVID-19 Infections in RAPPORT (IMPACT) | 500 | Observational | 15 Apr 2020 | Canada | Impact of anti-malarials on the development and severity of COVID-19in the anti-malarial group compared to the non-anti-malarial group (TF: 12 months ) |
| 7 | NCT04374942 | Does HCQ Before & During Patient Exposure Protect Healthcare Workers From Coronavirus? (HEROs) | 988 | CT | 30 Apr 2020 | Canada | Microbiologically confirmed COVID-19 (SARS-CoV-2 infection) (TF: samples collected at d- 0, 30, 60, 90 and 120 ) |
| 8 | NCT04350671 | Interferon Beta 1a in Hospitalized COVID-19 Patients (IB1aIC) | 40 | CT | 15 Apr 2020 | Iran | Time to clinical improvement (TF: from date of randomization until 14 d later) |
| 9 | NCT04369989 | Observational Study of COVID-19 Treatment Efficacy | 1000 | Observational | 14 Apr 2020 | US | Mortality during the COVID-19 treatment hospital encounter (TF: up to 6 wk )ICU admission during the COVID-19 treatment hospital encounter (TF: up to 6 wk )Ventilator use during the COVID-19 treatment hospital encounter (TF: up to 6 wk ) |
| 10 | NCT04349410 | The Fleming [FMTVDM) Directed COVID-19 Treatment Protocol (FMTVDM) | 500 | CT | 11 Apr 2020 | US | Improvement in FMTVDM Measurement with nuclear imaging (TF: 72 hrs ) |
| **Completed**  |
| 1 | NCT04261517 | Efficacy and Safety of HCQ for Treatment of COVID-19  | 30 | CT | 06 Feb 2020 | China | The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at d-3 , d-5, and d-7 (TF: 3 d, 5d, and 7d after randomization )The mortality rate of subjects at week 2 (TF: 14 d after randomization ) |
| 2 | NCT04389320 | Antimalarial and COVID-19 in Rheumatoid Arthritis | 60 | Observational | 15 Mar 2020 | Egypt | Immunoglobulin measurement (TF: 1 month ) |
| 3 | NCT04343768 | An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial (COVIFERON) | 60 | CT | 09 Apr 2020 | Iran | Time to clinical improvement (TF: from date of randomization until 14 d late) |
| 4 | NCT04374071 | Early Short Course Corticosteroids in COVID-19  | 250 | Observational  | 12 Mar 2020 | US | Transfer to ICU (TF: 14 d follow-up for every patient in each group )Need for mechanical ventilation (TF: 14 d follow-up for every patient in each group )Mortality (TF: 14 d follow-up for every patient in each group ) |
| 5 | NCT04338932 | COVID-19 and Deep Venous Thrombosis | 12 | Observational | 17 Apr 2020 | Belgium | The prevalence of a DVT in patients at the ICU. (TF: 1d at ICU ) |

Abbreviations – A/E: Adverse Effect, Apr: April, ARDS: Acute respiratory distress syndrome, CRP: C-reactive protein, D: Day, DVT: Deep vein thrombosis, ECG: Electrocardiogram, ER: Emergency, Feb: February, FMTVDM: Fleming method for tissue and vascular differentiation and metabolism, HCQ: Hydroxychloroquine, HCWs: Health care workers, Hr: Hour, ICU: Intensive care unit, IL: Interleukin, Jun: June, LOS: Length of stay, LRTI: Lower respiratory tract infection, Mar: March, NP: Not provided, NPS: Nasopharyngeal swab, RT-PCR: Reverse transcription polymerase chain reaction, TF: Time frame, URTI: Upper respiratory tract infection, US: United States, WHO: World Health Organization, Wk: Week